A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206)

Junko Eba; Hirotsugu Kenmotsu; Masahiro Tsuboi; Seiji Niho; Hiroshi Katayama; Taro Shibata; Shun ichi Watanabe; Noboru Yamamoto; Tomohide Tamura; Hisao Asamura

doi:10.1093/jjco/hyt233

A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206)

Junko Eba, Hirotsugu Kenmotsu, Masahiro Tsuboi, Seiji Niho, Hiroshi Katayama, Taro Shibata, Shun ichi Watanabe, Noboru Yamamoto, Tomohide Tamura, Hisao Asamura

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

A randomized Phase III trial commenced in Japan in March 2013. Post-operative adjuvant chemotherapy with etoposide plus cisplatin is the current standard treatment for resected pulmonary high-grade neuroendocrine carcinoma including small cell lung cancer and large cell neuroendocrine carcinoma. The purpose of this study is to confirm the superiority of irinotecan plus cisplatin in terms of overall survival over etoposide plus cisplatin as post-operative adjuvant chemotherapy for pathological Stage I-IIIA completely resected pulmonary high-grade neuroendocrine carcinoma patients. A total of 220 patients will be accrued from 54 Japanese institutions within 6 years. The primary endpoint is overall survival and the secondary endpoints are relapse-free survival, proportion of treatment completion, adverse events, serious adverse events and second malignancy.

Original language	English
Article number	hyt233
Pages (from-to)	379-382
Number of pages	4
Journal	Japanese journal of clinical oncology
Volume	44
Issue number	4
DOIs	https://doi.org/10.1093/jjco/hyt233
Publication status	Published - 2014 Apr
Externally published	Yes

Keywords

Adjuvant chemotherapy
High-grade neuroendocrine carcinoma
Lung neoplasms
Phase III

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jjco/hyt233

Cite this

Eba, J., Kenmotsu, H., Tsuboi, M., Niho, S., Katayama, H., Shibata, T., Watanabe, S. I., Yamamoto, N., Tamura, T., & Asamura, H. (2014). A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206). Japanese journal of clinical oncology, 44(4), 379-382. Article hyt233. https://doi.org/10.1093/jjco/hyt233

A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206). / Eba, Junko; Kenmotsu, Hirotsugu; Tsuboi, Masahiro et al.
In: Japanese journal of clinical oncology, Vol. 44, No. 4, hyt233, 04.2014, p. 379-382.

Research output: Contribution to journal › Article › peer-review

Eba, J, Kenmotsu, H, Tsuboi, M, Niho, S, Katayama, H, Shibata, T, Watanabe, SI, Yamamoto, N, Tamura, T & Asamura, H 2014, 'A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206)', Japanese journal of clinical oncology, vol. 44, no. 4, hyt233, pp. 379-382. https://doi.org/10.1093/jjco/hyt233

@article{732ca1f9f1d14d7490de972770fcfae4,

title = "A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206)",

abstract = "A randomized Phase III trial commenced in Japan in March 2013. Post-operative adjuvant chemotherapy with etoposide plus cisplatin is the current standard treatment for resected pulmonary high-grade neuroendocrine carcinoma including small cell lung cancer and large cell neuroendocrine carcinoma. The purpose of this study is to confirm the superiority of irinotecan plus cisplatin in terms of overall survival over etoposide plus cisplatin as post-operative adjuvant chemotherapy for pathological Stage I-IIIA completely resected pulmonary high-grade neuroendocrine carcinoma patients. A total of 220 patients will be accrued from 54 Japanese institutions within 6 years. The primary endpoint is overall survival and the secondary endpoints are relapse-free survival, proportion of treatment completion, adverse events, serious adverse events and second malignancy.",

keywords = "Adjuvant chemotherapy, High-grade neuroendocrine carcinoma, Lung neoplasms, Phase III",

author = "Junko Eba and Hirotsugu Kenmotsu and Masahiro Tsuboi and Seiji Niho and Hiroshi Katayama and Taro Shibata and Watanabe, {Shun ichi} and Noboru Yamamoto and Tomohide Tamura and Hisao Asamura",

note = "Funding Information: This study was supported by the National Cancer Center Research and Development Fund (23-A-16, 23-A-18).",

year = "2014",

month = apr,

doi = "10.1093/jjco/hyt233",

language = "English",

volume = "44",

pages = "379--382",

journal = "Japanese journal of clinical oncology",

issn = "0368-2811",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206)

AU - Eba, Junko

AU - Kenmotsu, Hirotsugu

AU - Tsuboi, Masahiro

AU - Niho, Seiji

AU - Katayama, Hiroshi

AU - Shibata, Taro

AU - Watanabe, Shun ichi

AU - Yamamoto, Noboru

AU - Tamura, Tomohide

AU - Asamura, Hisao

N1 - Funding Information: This study was supported by the National Cancer Center Research and Development Fund (23-A-16, 23-A-18).

PY - 2014/4

Y1 - 2014/4

N2 - A randomized Phase III trial commenced in Japan in March 2013. Post-operative adjuvant chemotherapy with etoposide plus cisplatin is the current standard treatment for resected pulmonary high-grade neuroendocrine carcinoma including small cell lung cancer and large cell neuroendocrine carcinoma. The purpose of this study is to confirm the superiority of irinotecan plus cisplatin in terms of overall survival over etoposide plus cisplatin as post-operative adjuvant chemotherapy for pathological Stage I-IIIA completely resected pulmonary high-grade neuroendocrine carcinoma patients. A total of 220 patients will be accrued from 54 Japanese institutions within 6 years. The primary endpoint is overall survival and the secondary endpoints are relapse-free survival, proportion of treatment completion, adverse events, serious adverse events and second malignancy.

AB - A randomized Phase III trial commenced in Japan in March 2013. Post-operative adjuvant chemotherapy with etoposide plus cisplatin is the current standard treatment for resected pulmonary high-grade neuroendocrine carcinoma including small cell lung cancer and large cell neuroendocrine carcinoma. The purpose of this study is to confirm the superiority of irinotecan plus cisplatin in terms of overall survival over etoposide plus cisplatin as post-operative adjuvant chemotherapy for pathological Stage I-IIIA completely resected pulmonary high-grade neuroendocrine carcinoma patients. A total of 220 patients will be accrued from 54 Japanese institutions within 6 years. The primary endpoint is overall survival and the secondary endpoints are relapse-free survival, proportion of treatment completion, adverse events, serious adverse events and second malignancy.

KW - Adjuvant chemotherapy

KW - High-grade neuroendocrine carcinoma

KW - Lung neoplasms

KW - Phase III

UR - http://www.scopus.com/inward/record.url?scp=84897475114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897475114&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyt233

DO - 10.1093/jjco/hyt233

M3 - Article

C2 - 24474818

AN - SCOPUS:84897475114

SN - 0368-2811

VL - 44

SP - 379

EP - 382

JO - Japanese journal of clinical oncology

JF - Japanese journal of clinical oncology

IS - 4

M1 - hyt233

ER -

A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this